Literature DB >> 8885289

The role of glutamate in behavioral and neurotoxic effects of methamphetamine.

T Ohmori1, T Abekawa, T Koyama.   

Abstract

Studies on the mechanisms of behavioral and neurochemical effects of amphetamine or methamphetamine (MA) have focused on the dopaminergic system. However, recent reports suggest that the glutamatergic system may be involved in the MA effects. Our laboratory has been conducting a series of experiments to further examine the role of glutamate in both behavioral and neurotoxic effects of MA. These studies include (1) behavioral studies on the effect of N-methyl-D-aspartate (NMDA) antagonists on the development of MA-induced behavioral sensitization, (2) neurochemical studies on the effects of NMDA antagonists on MA-induced neurotoxicity, and (3) in vivo microdialysis studies on the effects of MA on glutamate release. In the present paper, the authors comment on an important role of glutamatergic systems in the behavioral and toxic effects of MA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885289     DOI: 10.1016/0197-0186(95)00152-2

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  10 in total

1.  Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

Authors:  K Grasing; R Azevedo; S Karuppan; S Ghosh
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  The biochemical basis of synaptic plasticity and neurocomputation: a new theory.

Authors:  J Smythies
Journal:  Proc Biol Sci       Date:  1997-04-22       Impact factor: 5.349

3.  Distinct neurochemical adaptations within the nucleus accumbens produced by a history of self-administered vs non-contingently administered intravenous methamphetamine.

Authors:  Kevin D Lominac; Arianne D Sacramento; Karen K Szumlinski; Tod E Kippin
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 4.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons.

Authors:  Dianne Langford; Aline Grigorian; Rosemary Hurford; Anthony Adame; Leslie Crews; Eliezer Masliah
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

6.  On the mechanism of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats.

Authors:  M Miele; M A Mura; P Enrico; G Esposito; P A Serra; R Migheli; D Zangani; E Miele; M S Desole
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

7.  Dizocilpine inhibits amphetamine-induced formation of nitric oxide and amphetamine-induced release of amino acids and acetylcholine in the rat brain.

Authors:  Michaela M Kraus; Valentina Bashkatova; Anatoly Vanin; Athineos Philippu; Helmut Prast
Journal:  Neurochem Res       Date:  2002-03       Impact factor: 3.996

8.  The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion.

Authors:  J Smythies
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

9.  Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy.

Authors:  Michael J Taylor; Brian C Schweinsburg; Omar M Alhassoon; Assawin Gongvatana; Gregory G Brown; Corinna Young-Casey; Scott L Letendre; Igor Grant
Journal:  J Neurovirol       Date:  2007-04       Impact factor: 2.643

10.  Effects of the trace amine associated receptor 1 agonist RO5263397 on abuse-related behavioral indices of methamphetamine in rats.

Authors:  Li Jing; Yanan Zhang; Jun-Xu Li
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.